Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Free Cash Flow (2016 - 2026)

Conmed filings provide 17 years of Free Cash Flow readings, the most recent being $10.6 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 71.98% to $10.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $123.7 million, a 24.82% decrease, with the full-year FY2025 number at $150.9 million, down 1.95% from a year prior.
  • Free Cash Flow hit $10.6 million in Q1 2026 for Conmed, down from $41.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $51.5 million in Q4 2023 to a low of -$17.3 million in Q4 2022.
  • Median Free Cash Flow over the past 5 years was $27.1 million (2024), compared with a mean of $25.5 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 156.46% in 2022 and later surged 434.35% in 2024.
  • Conmed's Free Cash Flow stood at -$17.3 million in 2022, then soared by 398.37% to $51.5 million in 2023, then dropped by 23.75% to $39.3 million in 2024, then grew by 4.9% to $41.2 million in 2025, then tumbled by 74.34% to $10.6 million in 2026.
  • The last three reported values for Free Cash Flow were $10.6 million (Q1 2026), $41.2 million (Q4 2025), and $48.5 million (Q3 2025) per Business Quant data.